Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended that a Marketing Authorization may be issued in the European Union for Lonquex® (XM22 lipegfilgrastim) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). The CHMP positive opinion opens the way to a final approval decision from the European Commission expected within the next few months.
Help employers find you! Check out all the jobs and post your resume.
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended that a Marketing Authorization may be issued in the European Union for Lonquex® (XM22 lipegfilgrastim) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). The CHMP positive opinion opens the way to a final approval decision from the European Commission expected within the next few months.
Help employers find you! Check out all the jobs and post your resume.
